Inhibitors of Tumor Necrosis Factor (TNF) alpha (infliximab, etanercept, adalimumab) are nowadays widely used for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), not responding to conventional therapies. Anti-TNF alpha drugs have demonstrated great efficacy in slowing the disease, however, to date, concern still remains regarding acute and long-term toxicity related to TNF block. Increase in liver tests may be observed during treatment with anti-TNF agents, more often related to concomitant drugs (i.e, NSAIDS, methotrexate) or to reactivation of chronic HBV or HeV infections. However, liver damage directly induced by the drug has been described in patients treated with infliximab or adalimumab. To our knowledge, no cases of liver injury closely related to etanercept have been reported so far. We report the case of a patient with PsA who presented liver dysfunction during adalimumab, subsequently successfully treated with etanercept. (TNF)  alpha (infliximab, etanercept, adalimumab) are nowadays widely used for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), not responding to conventional therapies (1). Anti-TNF alpha drugs have demonstrated great efficacy in slowing the disease (2) . However, to date, concern still remains regarding acute and long-term toxicity related to TNF block (3) . Although liver toxicity during anti-TNF treatment has been primarily associated with concomitant hepatotoxic drugs, infection, or malignant diseases (4), cases of liver injury directly related to anti-TNF drugs have been reported (5) (6) .
Inhibitors of Tumor Necrosis Factor
We report the case of a patient with PsA who presented liver dysfunction during adalimumab, subsequently successfully treated with etanercept.
Case report
A 46-year-old white man, with a IS-year history of psoriasis (Ps) and an 8-year history of PsA with predominant axial involvement had been treated until 2006 with non-steroidal anti-inflammatory drugs (NSAIDS) and physical therapy. During the past year, his condition worsened with a persistent inflammatory back pain, lumbar and cervical spine limitation, and fatigue. Higher doses of NSAIDS gave no benefit. Bath ankylosing spondylitis disease activity index (BASDAI) rating was 4.6, swollen joint count was 2 and tender joint count was 3, with 30 minutes of morning stiffness.
Indication for anti-TNF alpha therapy was given. Laboratory tests showed increased CRP (18.1 mg/L, normal values < 1.0), normal ESR and transaminases (AST 20 mU/ml, ALT 19 mU/ml); HCV-Ab and HBV markers were negative. Screening for tuberculosis showed a normal chest X-ray and a negative PPD-test.
In May 2006 ada1imumab (40mg s.c. every other week) was started, with prompt response. NSAIDS were rapidly withdrawn, and after 2 months BASDAI rating was 0.7, swollen and tender joint count was 0, morning stiffness occurred for 10 minutes. CRP was 1.5 mg/L, AST was normal (33 mU/ml), while ALT showed a two-fold increase (96 mU/mL).
After 3 months, liver function tests were further increased (AST 66 mU/ml, ALT 252 mU/ml). Antinuclear (ANA), anti-neutrophil cytoplasmic (ANCA), liver-kidney microsomal (LKM) and anti-mitochondrial (AMA) autoantibodies were all negative and liver ultrasonography did not show any abnormal findings, therefore a drug-related hepatotoxicity was suspected. Since the patient was asymptomatic and physical examination showed only a limited range ofmotion ofcervical and lumbar spine, adalimumab was stopped. Laboratory tests repeated after 1 month showed normal AST (30 mU/ mL) with a slight increase ofALT (70 mU/mL). Due to worsening of joint and skin manifestations only partially controlled with NSAIDS, on September 2006 etanercept (50mg s.c. weekly) was started.
In October 2006 (2 months after adalimumab discontinuation, 1 month after etanercept) serum levels of both transaminases were normal (AST 23 mU/ml, ALT 39 mU/ml) and arthritis was well-controlled. During a IO-month follow-up of etanercept, liver function tests remained within the normal range.
DISCUSSION
Increase in liver tests may be observed during treatment with anti-TNF agents, more often related to concomitant drugs (i.e. NSAIDS, methotrexate) or to reactivation of chronic HBV or HCV infections. However, liver damage directly induced by the drug has been described in patients treated with infliximab or adalimumab. Acute liver failure and autoimmune hepatitis have been observed, albeit rarely, in patients receiving infliximab both in clinical trials and in post-marketing observation (7) and underlined by a warning from US Food and Drug Administration (8) . Increase in hepatic aminotransferase levels (ALT more frequently than AST) has been reported to occur between 2 weeks to more than I year after infliximab and mainly when infliximab is given as monotherapy or in combination with other immunosuppressive agents. If jaundice and/or liver enzyme elevations 2: 5 times the normal limits develop, the drugs should be discontinued, and a thorough investigation undertaken.
Increase in hepatic enzymes has rarely been reported during adalimumab (9) . Package insert reports hepatic necrosis occurring in less than 5% of patients treated with the drug. In clinical trials, elevation of aminotransferases (ALT more commonly than AS, mostly in the range of 1.5-3 times the normal limits) was observed in SA patients, mainly if adalimumab was given as monotherapy and in combination with other immunosoppressive drugs. Patients who developed ALT and AST elevation during infliximab as well as adalimumab were usually asymptomatic, the transaminase levels returned within the normal range with discontinuation of the drug, modification of concomitant medications, or even without any modification of the treatment.
To our knowledge, no cases ofliver injury closely related to etanercept have been reported so far.
GarciaAparicio et al (5) , and more recently Thiefin et al (6) , reported a case of severe hepatotoxicity (> 10 times the upper limit of normal) closely related to infliximab therapy and necessitating stopping the therapy. After normalisation of liver tests both the patients were treated successfully with etanercept. As for our patient, no increase ofALT and AST was observed after drug switching.
Although etanercept, adalimumab and infliximab share similar mechanisms of action, differences have been reported both in efficacy and adverse events; therefore, the lack of response or the appearance of an adverse event to one agent may not predict the lack of response or an adverse effect to another (10) .
In conclusion, although rare, we must be aware of the possibility of hepatotoxicity in patients treated with infliximab and adalimumab,. More studies are needed to confirm that etanercept might be a safe alternative in patients who develop liver injury during infliximab or adalimumab.
